Identification of factors important for the success of suicide gene therapy after a comparative study of Varicella zoster and Herpes simplex viral thymidine kinases efficacy on breast cancer cells
[en] One of the most frequently studied therapeutic strategies in the field of suicide gene therapy is based on the expression by tumor cells of the Herpes simplex virus thymidine kinase gene (HSVtk) followed by a ganciclovir (GCV) treatment. In order to investigate the potential of other enzyme/prodrug strategies, we studied in vitro and in vivo the ability of the Varicella zoster virus thymidine kinase gene (VZVtk) to act as a suicide gene and to kill non-transduced bystander cells, and compared this activity to that of its HSV counterpart. Four different antiviral compounds were tested as prodrugs. Our comparative study demonstrates the superiority of the HSVtk/GCV system among the different combinations tested and underlines the importance of both the tumor cell type and the prodrug in the success of a prodrug/suicide gene strategy.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Grignet, Christine ; Université de Liège - ULiège > Services administratifs généraux > Protection et hygiène du travail (SUPHT)
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Calberg-Bacq, C. M.
Language :
English
Title :
Identification of factors important for the success of suicide gene therapy after a comparative study of Varicella zoster and Herpes simplex viral thymidine kinases efficacy on breast cancer cells
Aghi, M., Kramm, C.M., Chou, T.C., Breakefield, X.O. and Chiocca, E.A., Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst. 1998, 90: 370-380.
Andrei, G., Snoeck, R., Reymen, D., Liesnard, C., Goubau, P., Desmyter, J. and De Clercq, E., Comparative activity of selected antiviral compounds against clinical isolates of Varicella zoster virus. Eur. J. Clin. Microbiol. Infect. Dis. 1995, 14: 318-329.
Ashida, N., Sakata, S., Kano, F., Nishitani, M., Watanabe, Y. and Machida, H., In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU. Antiviral Res. 1994, 25: 179-184.
Bai, S., Du, L., Liu, W., Whittle, I.R. and He, L., Tentative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system. Biochem. Biophys. Res. Commun. 1999, 259: 455-459.
Balzarini, J., De Clercq, E., Ayusawa, D. and Seno, T., Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett. 1985, 185: 95-100.
Balzarini, J., Bohman, C., Walker, R.T. and De Clercq, E., Comparative cytostatic activity of different antiherpetic drugs against herpes-simplex virus thymidine kinase gene-transfected tumor-cells. Mol. Pharmacol. 1994, 45: 1253-1258.
Balzarini, J., Degreve, B., Andrei, G., Neyts, J., Sandvold, M., Myhren, F. and De Clercq, E., Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther. 1998, 5: 419-426.
Barba, D., Hardin, J., Sadelain, M. and Gage, F.H., Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 1994, 91: 4348-4352.
Bevans, C.G., Kordel, M., Rhee, S.K. and Harris, A.L., Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J. Biol. Chem. 1998, 273: 2808-2816.
Bi, W.L., Parysek, L.M., Warnick, R. and Stambrook, P.J., In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum. Gene Ther. 1993, 4: 725-731.
Bird, L.E., Ren, J., Wright, A., Leslie, K.D., Degreve, B., Balzarini, J. and Stammers, D.K., Crystal structure of varicella zoster virus thymidine kinase. J. Biol. Chem. 2003, 278: 24680-24687.
Black, M.E., Kokoris, M.S. and Sabo, P., Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001, 61: 3022-3026.
Boucher, P.D., Ostruszka, L.J., Murphy, P.J. and Shewach, D.S., Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 2002, 9: 1023-1030.
Boucher, P.D., Ostruszka, L.J. and Shewach, D.S., Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea. Cancer Res. 2000, 60: 1631-1636.
Boucher, P.D., Ruch, R.J. and Shewach, D.S., Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum. Gene Ther. 1998, 9: 801-814.
Brockstedt, D.G., Diagana, M., Zhang, Y., Tran, K., Belmar, N., Meier, M., Yang, A., Boissiere, F., Lin, A. and Chiang,Y., Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol. Ther. 2002, 6: 627-636.
Burrows, F.J., Gore, M., Smiley, W.R., Kanemitsu, M.Y., Jolly, D.J., Read, S.B., Nicholas, T. and Kruse, C.A., Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther. 2002, 9: 87-95.
Cao, F., Eckert, R., Elfgang, C., Nitsche, J.M., Snyder, S.A., Ulser, D.F., Willecke, K. and Nicholson, B.J., A quantitative analysis of connexin-specific permeability differences of gap junctions expressed in HeLa transfectants and Xenopus oocytes. J. Cell Sci. 1998, 111: 31-43.
Cheng, Y.C., Dutschman, G., Fox, J.J., Watanabe, K.A. and Machida, H., Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob. Agents Chemother. 1981, 20: 420-423.
Cirenei, N., Colombo, B.M., Mesnil, M., Benedetti, S., Yamasaki, H. and Finocchiaro, G., In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy. Gene Ther. 1998, 5: 1221-1226.
Cool, V., Pirotte, B., Gerard, C., Dargent, J.L., Baudson, N., Levivier, M., Goldman, S., Hildebrand, J., Brotchi, J. and Velu, T., Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther. 1996, 7: 627-635.
Davidson, J.S., Baumgarten, I.M. and Harley, E.H., Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid. Biochem. Biophys. Res. Commun. 1986, 134: 29-36.
De Clercq, E., Potential of bromovinyldeoxyuridine in anticancer chemotherapy. Anticancer Res. 1986, 6: 549-556.
Degreve, B., Andrei, G., Izquierdo, M., Piette, J., Morin. K., Knaus, E.E., Wiebe, L.I., Basrah, I., Walker, R.T., De Clercq, E. and Balzarini, J., Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Ther. 1997, 4: 1107-1114.
Degreve, B., De Clercq E. and Balzarini, J., Bystander effect of purine nucleoside analogues in HSV-1 tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther. 1999, 6: 162-170.
Descamps, J., Sehgal, R.K., De Clercq, E. and Allaudeen, H.S., Inhibitory effect of E-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on herpes simplex virus replication and DNA synthesis. J. Virol. 1982, 43: 332-336.
Dilber, M.S., Abedi, M.R., Christensson, B., Bjorkstrand, B., Kidder, G.M., Naus, C.C., Gahrton, G. and Smith, C.I., Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 1997, 57: 1523-1528.
Eghbali, B., Kessler, J.A., Reid, L.M., Roy, C. and Spray, D.C., Involvement of gap junctions intumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc. Natl. Acad. Sci. USA 1991, 88: 10701-10705.
Elshami, A.A., Saavedra, A., Zhang, H., Kucharczuk, J.C., Spray, D.C., Fishman, G.I., Amin, K.M., Kaiser, L.R. and Albelda, S.M., Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996, 3: 85-92.
Fernstrom, M.J., Koffler, L.D., Abou-Rjaily G., Boucher, P.D., Shewach, D.S. and Ruch, R.J., Neoplastic reversal of human ovarian carcinoma cells transfected with connexin43. Exp. Mol. Pathol. 2002, 73: 54-60.
Pick, J., Barker, F.G., Dazin, P., Westphale, E.M., Beyer, E.C. and Israel, M.A., The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 1995, 92: 11071-11075.
Fillat, C., Carrio, M., Cascante, A. and Sangro, B., Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr. Gene Ther. 2003, 3: 13-26.
Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.L. and Abraham, G.N., The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993, 53: 5274-5283.
Gagandeep, S., Brew, R., Green, B., Christmas, S.E., Klatzmann, D., Poston, G.J. and Kinsella, A.R., Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther. 1996, 3: 83-88.
Grignet-Debrus, C. and Calberg-Bacq, C.M., Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther. 1997, 4: 560-569.
Grignet-Debrus, C., Cool, V., Baudson, N., Degreve, B., Balzarini, J., De Leval L., Debrus, S., Velu, T. and Calberg-Bacq, C.M., Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5- (2-bromovinyl)-1-beta-D- arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Cancer Gene Ther. 2000, 7: 215-223.
Grignet-Debrus, C., Cool, V., Baudson, N., Velu, T. and Calberg-Bacq, C.M., The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. 2000, 7: 1456-1468.
Hirschi, K.K., Xu, C.E., Tsukamoto, T. and Sager, R., Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ. 1996, 7: 861-870.
Hoganson, D.K., Batra, R.K., Olsen, J.C. and Boucher, R.C., Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 1996, 56: 1315-1323.
Ishii-Morita, H., Agbaria, R., Mullen, C.A., Hirano, H., Koeplin, D.A., Ram, Z., Oldfield, E.H., Johns, D.G. and Blaese, R.M., Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997, 4: 244-251.
Kianmanesh, A.R., Perrin, H., Panis, Y., Fabre, M., Nagy, H.J., Houssin, D. and Klatzmann, D., A "distant" bystander effect of suicide gene therapy: regression of non-transduced tumors together with a distant transduced tumor. Hum. Gene Ther. 1997, 8: 1807-1814.
Labarca, C. and Paigen, K., A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 1980, 102: 344-352.
Lee, S.W., Tomasetto, C., Paul, D., Keyomarsi, K. and Sager, R., Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J. Cell Biol. 1992, 118: 1213-1221.
Li, H., Liu, T.F., Lazrak, A., Peracchia, C., Goldberg, G.S., Lampe, P.D. and Johnson, R.G., Properties and regulation of gap junctional hemichannels in the plasma membranes of cultured cells. J. Cell Biol. 1996, 134: 1019-1030.
Majumdar, A.S., Zolotorev, A., Samuel, S., Tran, K., Vertin, B., Hall-Meier, M., Antoni, B.A., Adeline, E., Philip, M. and Philip, R., Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000, 7: 1086-1099.
Mesnil, M., Krutovskikh, V., Piccoli, C., Elfgang, C., Traub, O., Willecke, K. and Yamasaki, H., Negative growth control of HeLa cells by connexin genes: connexin species specificity. Cancer Res. 1995, 55: 629-639.
Mesnil, M., Piccoli, C., Tiraby G., Willecke, K. and Yamasaki, H., Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 1996, 93: 1831-1835.
Mesnil, M., Piccoli, C. and Yamasaki, H., A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res. 1997, 57: 2929-2932.
Mesnil, M. and Yamasaki, H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000, 60: 3989-3999.
Monaghan, P., Clarke, C., Perusinghe, N.P., Moss, D.W., Chen, X.Y. and Evans, W.H., Gap junction distribution and connexin expression in human breast. Exp. Cell. Res. 1996, 223: 29-38.
Moolten, F.L., Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986, 46: 5276-5281.
Naesens, L. and De Clercq, E., Recent developments in herpesvirus therapy. Herpes 2001, 8: 12-16.
Namba, H., Iwadate, Y., Kawamura, K., Sakiyama, S. and Tagawa, M., Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cells. Cancer Gene Ther. 2001, 8: 414-420.
Nicholas, T.W., Read, S.B., Burrows, F.J. and Kruse, C.A., Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol. Histopathol. 2003, 18: 495-507.
Noel, A., Pauw-Gillet, M.C., Purnell, G., Nusgens, B., Lapiere, C.M. and Foidart, J.M., Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br. J. Cancer 1993, 68: 909-915.
Pulkkanen, K.J., Laukkanen, J.M., Fuxe, J., Kettunen, M.I., Rehn, M., Kannasto, J.M., Parkkinen, J.J., Kauppinen, R.A. and Pettersson, R.F., The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther. 2002, 9: 908-916.
Rogulski, K.R., Kim, J.H., Kim, S.H. and Freytag, S.O., Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 1997, 8: 73-85.
Rubsam, L.Z., Davidson, B.L. and Shewach, D.S., Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res. 1998, 58: 3873-82.
Rubsam, L.Z., Boucher, P.D., Murphy, P.J., KuKuruga, M. and Shewach, D.S., Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 1999, 59: 669-675.
Samejima, Y. and Meruelo, D., 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther. 1995, 2: 50-58.
Santi, D.V., Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase. J. Med. Chem. 1980, 23: 103-111.
Sasadeusz, J.J. and Sacks, S.L., Systemic antivirals in herpesvirus infections. Dermatol. Clin. 1993, 11: 171-185.
Sawyer, M.H., Inchauspe, G., Biron, K.K., Waters, D.J., Straus, S.E. and Ostrove, J.M., Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of Varicella-zoster virus. J. Gen. Virol. 1988, 69: 2585-2593.
Uckert, W., Kammertons, T., Haack, K., Qin, Z., Gebert, J., Schendel, D.J. and Blankenstein, T., Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. 1998, 9: 855-865.
Veenstra, R.D., Wang, H.Z., Beblo, D.A., Chilton, M.G., Harris, A.L., Beyer, E.C. and Brink, P.R., Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ. Res. 1995, 77: 1156-1165.
Vrionis, F.D., Wu, J.K., Qi, P., Waltzman, M., Cherington, V. and Spray, D.C., The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 1997, 4: 577-585.
Whitley, R.J., Sorivudine: a promising drug for the treatment of Varicella-zoster virus infection. Neurology 1995, 45: S73-S75.
Wiewrodt, R., Amin, K., Kiefer, M., Jovanovic, V.P., Kapoor, V., Force, S., Chang, M., Lanuti, M., Black, M.E., Kaiser, L.R. and Albelda, S.M., Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther. 2003, 10: 353-364.
Wutzler, P., De Clercq, E., Wutke, K. and Farber, I., Oral brivudin vs intravenous acyclovir in the treatment of herpes-zoster in immunocompromised patients - a randomized double-blind trial. J. Med. Virol. 1995, 46: 252-257.
Yamamoto, S., Yamano, T., Tanaka, M., Hoon, D.S., Takao, S., Morishita, R., Aikou, T. and Kaneda, Y., A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther. 2003, 10: 179-186.
Yang, L., Chiang, Y., Lenz, H.J., Danenberg, K.D., Spears, C.P., Gordon, E.M., Anderson, W.F. and Parekh, D., Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther. 1998, 9: 719-728.
Yokota, T., Konno, K., Mori, S., Shigeta, S., Kumagai, M., Watanabe, Y. and Machida, H., Mechanism of selective inhibition of Varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Mol. Pharmacol. 1989, 36: 312-316.
